Qatar Cardiometabolic Registry

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorHamad Medical Corporation

About this trial

Type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD) are closely related. T2DM risk equivalent for CVD and it remains the major cause of death in T2DM. Thus, patients with T2DM and CVD disease are at very high-risk of CVD-related mortality. Therefore, more aggressive metabolic and hemodynamic control is required in such patients to improve the prognosis. We recently initiated a cardio-metabolic clinical service at the Heart Hospital, where T2DM patients with existing CVD are simultaneously examined by Cardiologist and Diabetologist for optimal metabolic and hemodynamic control. We would like to start a clinical registry for all patients who attend this clinical service to collect import clinical data about this population. This registry will serve an important source for future clinical research in the field.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients with type 2 diabetes mellitus

Newly diagnosed heart disease, such as ischemic heart disease, heart failure.

Disqualifiers

Patients who do not have type 2 diabetes mellitus

Preexisting heart disease

Trial population

Patients with type 2 diabetes mellitus and cardiovascular disease

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Trial outcomes

Primary outcomes

1

Mortality

Time frame
Ten years (15/09/2017 to 31/12/2027)

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.